Two Sigma Advisers’s Hepion Pharmaceuticals HEPA Stock Holding History

Two Sigma Advisers’s Portfolio HEPA Stock Details HEPA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-26	Closed	-$20.1K	–	2499
2023 Q1	$20.1K	Hold	26	–	–	﹤0.01%	2516
2022 Q4	$7.78K	Sell	26 -4	-13%	-$1.69K	﹤0.01%	2465
2022 Q3	$15K	Sell	30 -16	-35%	-$9.77K	﹤0.01%	2461
2022 Q2	$26K	Sell	46 -36	-44%	-$30K	﹤0.01%	2533
2022 Q1	$106K	Sell	82 -25	-23%	-$27.6K	﹤0.01%	2498
2021 Q4	$121K	Sell	107 -16	-13%	-$21.9K	﹤0.01%	2386
2021 Q3	$188K	Sell	123 -748	-86%	-$1.2M	﹤0.01%	2260
2021 Q2	$1.73M	Buy	871 +748	+608%	+$1.37M	﹤0.01%	1364
2021 Q1	$227K	Buy	+123	New	+$270K	﹤0.01%	2320

Other funds holding HEPA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Two Sigma Advisers's HEPA Position: Q2 2023 in Review

Two Sigma Advisers sold out of Hepion Pharmaceuticals (HEPA) in Q2 2023, closing a stake of 26 shares — an estimated $20.1K sold.

Two Sigma Advisers first reported a position in HEPA in Q1 2021 and held it in 9 quarters. The position peaked at $1.73M in Q2 2021. 16 funds tracked by Wall St. Rank hold HEPA as of Q2 2023.

Two Sigma Advisers reported no remaining Hepion Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Two Sigma Advisers sold 26 Hepion Pharmaceuticals shares in Q2 2023, an estimated $20.1K.
Two Sigma Advisers first reported a position in Hepion Pharmaceuticals in Q1 2021 and held it in 9 quarters.
Two Sigma Advisers's Hepion Pharmaceuticals position peaked at $1.73M in Q2 2021.
16 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q2 2023.

Based on Two Sigma Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.